Clock genes, circadian pacemaker resides in the paired suprachiasmatic nuclei (SCN), control various circadian rhythms in many biological processes such as physiology and behavior. Clock gene regulates many diseases such as cancer, immunological dysfunction, metabolic syndrome and sleep disorders etc. Dosing time influences the effectiveness and toxicity of many drugs. The pharmacodynamics of medications as well as pharmacokinetics influences chronopharmacological phenomena. For example, the therapies for chronic kidney disease (CKD) are urgently needed because of a global health problem. The mechanism of the cardiac complications in mice with CKD had been related the GRP68 in circulating monocytes and serum accumulation of retinol. Development of a strategy to suppress retinol accumulation will be useful to prevent the cardiac complications of CKD. To establish the chrono-drug discovery and development, the essential criteria for new drug discovery and development are to increase the probability of success in clinical trials for proof of concept, which involves the development of a promising strategy for drug target identification and validation to decrease the gap between non-clinical and clinical trials. The collaboration among the academia, the basic research institutes, the hospital institutions, the government, and the industry such as pharmaceutical companies, is essential to achieve the purpose described above. Additionally, to promote the method and development of new modality drug discovery demonstrated by antibodies, nucleic acids, and clock genes is critical for academic research, along with a combination of chemical and biological information is essential. Overall, clock genes are critical candidates for therapy associated with immune system and the severity of infections, as shown by the accumulated data. Therefore, global collaboration among the academia, the hospital, the government and the industry is essential to decrease the gap between drug discovery and development.